Asset Details
Do you wish to reserve the book?
Correction: CAR T cell therapy for central nervous system solid tumors: current progress and future directions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Correction: CAR T cell therapy for central nervous system solid tumors: current progress and future directions
Do you wish to request the book?
Correction: CAR T cell therapy for central nervous system solid tumors: current progress and future directions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Correction: CAR T cell therapy for central nervous system solid tumors: current progress and future directions
2025
Overview
“3/5 SD tumor necrosis; all patients without C7R progressed after 1st infusion; longer PFS in C7R group; CAR T cell expansion and persistence in group with and without C7R; intratumor C7R transgene and residual GD2 detected in one patient analyzed; grade 4 CRS in one patient” There was a mistake in Table 1 as published. “no antigen loss; in vivo CAR T cell expansion; CAR T tumor infiltration in PD case after IV dose; regression of spinal cord tumor but not metastasis after IV dose; Tregs and MDSCs increase post therapy; dose limiting toxicity for IV but not ICV; manageable TIAN in all patients after ICV infusion correlated with CCL2 upregulation; PD associated with TGF-β upregulation; 57% transduction efficiency”. (2025) (17) IL13Rα2+EGFR EGFR-IL13Rα2-BBζ bicistronic CAR T cells 18 multifocal rGBM (EGFR+) 1-2.5e7 cells (up to 2 doses) ICV Ommaya reservoir 8/13 tumor shrinkage; 1PR, 8SD Pseudoprogression in 2 patients; CAR T cell expansion (less after second dose); CAR T cells in blood; grade 3 toxicity in 56% patients; manageable acute neurotoxicity 12-48h post-infusion (different from ICANS and TIAN); 2.5e7 cells max tolerated dose; IFN-γ, IL-2,IL-6, and TNF-α in CSF Brown et al. (2024) (22) EGFRvIII + EGFR EGFRvIII-BBζ CAR T cells (anti-EGFRwt TEAM secretion) 3 rGBM (EGFRvIII+ IDHwt) 1e7 cells (1-2 doses) ICV Ommaya reservoir (10 ml cells over 10 min) – 3/3 tumor shrinkage antigen loss; CAR T cells in blood Bagley et al. (2019) (25) EGFRvIII EGFRvIII-28BBζ CAR T cells 18 rGBM (EGFRvIII+) 1e7-6e10 cells (up to 10 doses) IV – cyclophosphamide + fludarabine + IL-2 1/18 long term survival 66% transduction efficiency; severe hypoxia at highest dose (without IL-2) likely due to congestion of pulmonary vasculature O'Rourke et al. (2021) (32) B7-H3 B7-H3-BBζ CAR T cells 1 rGBM (heterogeneous B7-H3 expression) 0.4-2e7 cells (6 weekly doses) IT Ommaya reservoir (1 ml cells over 10 min + 1 ml PFNS flush over 5 min) – 1/1 tumor shrinkage probable antigen loss; limited
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
